Johnson & Johnson scored a victory in its battle against a surgical funder that allegedly profiteered on personal injury settlements for patients suing over J&J's all-metal hip implants, as a federal judge granted the company's request to see information about the funder's questionable payments for plaintiffs' surgeries.
Johnson & Johnson's new R&D outpost in Toronto isn't slated to open until the spring, but the company has already inked a pair of collaboration deals worth up to $690 million as it settles into the local biotech scene.
Johnson & Johnson may be embarking on a $10 billion share repurchase program, but that doesn't mean it doesn't have room to make deals.
Analysts have speculated that Eli Lilly and Boehringer Ingelheim's SGLT2 rivals may see their own sales rise, thanks to data showing the pair's med, Jardiance, reduced the combined risk of heart attack, stroke and death from cardiovascular causes in high-risk Type 2 diabetes patients. Johnson & Johnson, which makes challenger Invokana, agrees.
This year's Fierce 15 companies are all working on big ideas such as cutting-edge patient monitoring, smartphone-based imaging, biodegradable valves and vessels, more accurate knee implants, intestinal ablation to treat diabetes, energy-delivering angioplasty balloons, an implantable cell-based pancreas replacement, and connected asthma inhalers as well as the consumerization of health devices and diagnostics.
In the second quarter, Johnson & Johnson set the tone on China outlooks for big pharma, noting rapid policy and consumer changes that were leading to a slowdown in business for most multinationals.
Johnson and Johnson's top line didn't look so hot in Q3, and once again, the company has the ultracompetitive hepatitis C field to blame.
Just three weeks after it struck up a $28.5 million government partnership to advance its Ebola vaccine, Johnson & Johnson announced on Friday that it is starting a safety and immunogenicity trial in Sierra Leone for its Ebola candidate.
California wants to cap drug prices, but Big Pharma isn't having it. Amid growing backlash over drug pricing, companies such as Johnson & Johnson and Bristol-Myers Squibb are funneling millions of dollars into stamping out a new proposal that would curb drug spending in the state.
Want a surefire path to an Office of Prescription Drug Promotion (OPDP) warning letter? Leave side effects out of a drug promo, a new analysis says. As a team of Johnson & Johnson execs found, 60% of the FDA warning letters and untitled letters issued by OPDP between 2013 and 2015 cited pharma for omitting risk information in promotional materials.